Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study) Full Text available with Trip Pro

Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study) Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Gastroenterology Actions . 2021 Mar;160(4):1097-1105. doi: 10.1053/j.gastro.2020.11.049. Epub 2020 Dec 9. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study) , , , , , , , Affiliations Expand Affiliations 1 The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Medical

2021 EvidenceUpdates

2. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

chemotherapy for stage II/III colon cancer (CCOG-1302 study) , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Gastroenterological Surgery, Nagoya University Hospital, Nagoya, Japan. Electronic address: goro@med.nagoya-u.ac.jp. 2 Department of Surgery, Tokai Central Hospital, Kagamihara, Japan. 3 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 4 Department of Surgery, Konan Kosei (...) Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study) Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features

2021 EvidenceUpdates

3. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial Full Text available with Trip Pro

Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Gastroenterology Actions . 2021 Mar;160(4):1085-1096.e5. doi: 10.1053/j.gastro.2020.11.037. Epub 2020 Nov 21. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Section for Colorectal

2021 EvidenceUpdates

4. Bowel cancer screening: guidelines for colonoscopy

Bowel cancer screening: guidelines for colonoscopy Bowel cancer screening: guidelines for colonoscopy - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional cookies You can at any time. Hide this message Show (...) or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check what you need to do Guidance Bowel cancer screening: guidelines for colonoscopy This guidance sets out the process for colonoscopy in the NHS bowel cancer screening programme. From: Published: 1 February 2011 Last updated: 18 February 2021, Applies to: England Documents HTML Details This guidance sets out the process for colonoscopy in the NHS bowel cancer screening programme. It replaces the Quality Assurance Guidelines

2021 Public Health England

5. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial Full Text available with Trip Pro

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Feb 9;JCO2002447. doi: 10.1200/JCO.20.02447. Online ahead of print. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients

2021 EvidenceUpdates

6. Text Messaging and Opt-out Mailed Outreach in Colorectal Cancer Screening: a Randomized Clinical Trial

Text Messaging and Opt-out Mailed Outreach in Colorectal Cancer Screening: a Randomized Clinical Trial Text Messaging and Opt-out Mailed Outreach in Colorectal Cancer Screening: a Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Gen Intern Med Actions . 2021 Jan 28. doi: 10.1007/s11606-020-06415-8. Online ahead of print. Text Messaging and Opt-out Mailed Outreach in Colorectal Cancer Screening: a Randomized Clinical Trial , , , , Affiliations Expand Affiliations 1 Center for Health Care Innovation, University of Pennsylvania, Philadelphia, PA, USA. s.huf@imperial.ac.uk. 2 The Commonwealth Fund, Harkness

2021 EvidenceUpdates

7. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Université de Paris and Department of Gastroenterology and Gastrointestinal Oncology, Georges-Pompidou European Hospital, Paris, France. 20 Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 21 Department of Health Science Research, Mayo Clinic, Rochester, MN, USA. Electronic address: shi.qian2@mayo.edu. PMID: 33271092 PMCID: PMC7786835 (available on 2021-12-01 ) DOI: Item in Clipboard Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA (...) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2021 EvidenceUpdates

8. Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer

, Narrow Band Imaging International Colorectal Endoscopic; OR, odds ratio; RR, relative risk; USMSTF, US Multi-Society Task Force on Colorectal Cancer. © 2020 by the American College of Gastroenterology, AGA Institute, and the American Society for Gastrointestinal Endoscopy. The American Journal of Gastroenterology: doi: 10.14309/ajg.0000000000001013 Free Metrics Colorectal polyps are the precursors for most colorectal cancers (CRCs). Some colorectal polyps accumulate enough mutations to develop high (...) most often raised by malignant polyps is whether a patient with an endoscopically resected colorectal lesion with submucosal invasion requires surgical resection of the colorectal segment from which the lesion was removed. Some malignant polyps can be managed endoscopically because the risk of residual cancer in the bowel wall and/or adjacent lymph nodes is very low. Other endoscopically resected malignant polyps are best managed by surgical resection because endoscopic resection alone

2021 American College of Gastroenterology

9. Pembrolizumab (Keytruda) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

Pembrolizumab (Keytruda) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer - Repository of AIHTA GmbH English | Browse - - - Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer Grössmann, N. (2020): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

2021 Austrian Institute of Health Technology Assessment

10. Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study Full Text available with Trip Pro

Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This project was not successful in its aim due to failure to achieve a reliable cell counting system. {{author}} {{($index , , , , & . John N Primrose 1, * , Siân A Pugh 1, 2 , Gareth Thomas 1 , Matthew Ellis 1 , Karwan Moutasim 1, 3 , David Mant 4 1 Cancer Sciences Division, University of Southampton

2021 NIHR HTA programme

11. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

that were outstanding after the technical engagement stage. The condition The condition There is an unmet need for treatments for BRAF V600E There is an unmet need for treatments for BRAF V600E mutation-positive metastatic colorectal cancer mutation-positive metastatic colorectal cancer 3.1 Colorectal cancer is a malignant tumour arising from the lining of the large intestine (colon and rectum). BRAF is a human gene that encodes the protein B-Raf, which influences cell growth. Metastatic colorectal (...) Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer T echnology appraisal guidance Published: 6 January 2021 www.nice.org.uk/guidance/ta668 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer Full Text available with Trip Pro

of the submucosa, respectively. Kikuchi R. Takano M. Takagi K. et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995; 38 : 1286-1295 The Kikuchi classification system is presented in . The difficulty in implementing the Kikuchi system is that the entire submucosa is not typically present in endoscopic resection specimens. For that reason, the Kikuchi system has been largely replaced by measuring the depth of submucosal invasion with an optical (...) resection of the colorectal segment from which the lesion was removed. Some malignant polyps can be managed endoscopically because the risk of residual cancer in the bowel wall and/or adjacent lymph nodes is very low. Other endoscopically resected malignant polyps are best managed by surgical resection because endoscopic resection alone is accompanied by a very high risk of residual cancer and/or lymph node metastases. Optimal selection of patients with malignant polyps for endoscopic surveillance vs

2020 American Gastroenterological Association Institute

13. Randomized Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake

Randomized Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake Randomized Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) Controlled Trial of Personalized Colorectal Cancer Risk Assessment vs Education to Promote Screening Uptake , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 2 Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 3 Division of Gastroenterology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 4 Division

2020 EvidenceUpdates

14. Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial

Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) . 2020 Sep 11;pnaa259. doi: 10.1093/pm/pnaa259. Online ahead of print. Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial , , , , Affiliations Expand Affiliations 1 Anesthesia, Intensive Care and Pain Management, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. 2 Pediatric Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. PMID: 32914161 DOI: Item

2020 EvidenceUpdates

15. AGA Clinical Practice Update on Young Adult Onset Colorectal Cancer Diagnosis and Management: Expert Review Full Text available with Trip Pro

in bowel habit, abdominal pain, iron deficiency anemia. Best Practice Advice 2 Clinicians should obtain family history of colorectal and other cancers in first and second degree relatives of patients with young adult–onset CRC and discuss genetic evaluation with germline genetic testing either in targeted genes based on phenotypic presentation or in multiplex gene panels regardless of family history. Best Practice Advice 3 Clinicians should present the role of fertility preservation prior to cancer (...) Lynch syndrome MSH2 Bailey C.E. Hu C.-Y. You Y.N. et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 2015; 150 : 17-22 EPCAM Autosomal dominant Colorectal Endometrial Ovary Stomach Hepatobiliary Upper urinary tract Pancreas Small Bowel CNS (Glioblastoma) 49 (29–85) 57 (22–82) 20 (1–66) 11–19 2–7 4–5 3–4 1–4 1–3 Age 20–25 y: Colonoscopy every 1–2 y Flexible sigmoidoscopy every 1–2 y post-IRA Consider annual endometrial

2020 American Gastroenterological Association Institute

16. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age

Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) : 10.1053/j.gastro.2020.05.049. Epub 2020 May 20. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age , , , , , , Affiliations Expand Affiliations 1 National Institute for Health Research Birmingham Biomedical Research Centre, Centre for Liver and Gastroenterology Research, University of Birmingham, Birmingham, United Kingdom; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United

2020 EvidenceUpdates

17. Identifying Features of Screening Approaches for People at Increased Risk of Colorectal Cancer

the guidelines when defining individuals at average CRC risk, which typically included those who are above the age of 50 years with no personal or family history of CRC, with no risk factors (e.g., hereditary syndromes such as familial adenomatous polyposis or Lynch syndrome), without a history of abdominal or pelvic radiation due to previous cancer, or a history of inflammatory bowel disease.(4-9) One guideline from 2017 by the US Multi-Society Task Force on Colorectal Cancer recommended that the African (...) of 60 • History of inflammatory bowel disease • Suspected or confirmed hereditary CRC syndrome • Suspected or confirmed history of abdominal or pelvic radiation • Family history and genetic counselling referrals for hereditary syndromes Identifying Features of Screening Approaches for People at Increased Risk for Colorectal Cancer 12 Evidence >> Insight >> Action Evidence source Document characteristics Average CRC risk Increased CRC risk Screening criteria Features of approaches for managing CRC

2020 McMaster Health Forum

18. Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer Oregon Health Authority : Evidence-based Reports Blog : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Evidence-based Reports Blog menu Site Navigation Evidence-based Reports Blog Full Width Column 1 Select Ablation for Atrial Fibrillation Acellular Dermal Matrix for Post-Mastectomy Breast Reconstruction Compliance (...) ={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null); 0x0 0x1 ContentType 0x01 898 BlogTopic Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

2020 Oregon Health Evidence Review Commission

19. Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review Full Text available with Trip Pro

Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review | medRxiv Search for this keyword Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review Elizabeth Lemmon , Catherine Hanna , Peter S Hall , Eva Morris doi: https://doi.org/10.1101/2020.09.29.20203679 Elizabeth Lemmon 1 (...) University of Edinburgh; For correspondence: Catherine Hanna 2 University of Glasgow; For correspondence: Peter S Hall 1 University of Edinburgh; For correspondence: Eva Morris 3 University of Oxford For correspondence: Abstract Introduction: Several forces are contributing to an increase in the number of people living with and surviving colorectal cancer (CRC). However, due to the lack of available data, little is known about those implications. In recent years, the use of administrative records

2020 Cold Spring Harbor Laboratory

20. Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness Full Text available with Trip Pro

in Colon Cancer patients undergoing chemotherapy. Med Sci Sports Exerc. 2016;48(5):767–75. 55. van Rooijen SJ, Engelen MA, Scheede-Bergdahl C, Carli F, Roumen RMH, Slooter GD, et al. Systematic review of exercise training in colorectal cancer patients during treatment. Scand J Med Sci Sports. 2018;28(2):360–70. 56. Spence R, DiSipio T, Schmitz K, Hayes S. Is unsupervised exercise following breast cancer safe for all women? Int J Phys Med Rehabil. 2014;2(197):1–8. 57. Cancer Research UK. Bowel Cancer (...) with adjuvant treatments include pain, weakness, fatigue, diarrhea, cardiotoxicity, bowel dysfunction, anorectal dysfunction, sexual dysfunction, anxiety, depression, reduced physical fitness and function, and reduced quality of life (QoL, [ , , , ]). Impairments in social and role functioning, particularly the ability to participate in community activities, social activities, and undertake work and employment have also been reported by colorectal cancer survivors [ ]. Further, more than 30% of patients

2020 International Journal of Behavioral Nutrition and Physical Activity